Women's Endocrine-Metabolic Axis: Formulation Technologies and Active Ingredients for Food, Dietary Supplements, and Medical Foods
The endocrine-metabolic axis in PCOS and in the context of fertility is strongly modulated by insulin signaling and oxidative stress, which justifies designing products combining insulin sensitizers (inositols) and antioxidants (e.g., CoQ10, NAC, resveratrol) in patient-acceptable formats (e.g., sachets) and with improved bioavailability (e.g., phospholipid carriers, SEDDS).[1–5]
Key Product-Formulation Conclusions:
- The ratio of myo‑inositol (MI) : D‑chiro‑inositol (DCI) is best clinically documented in comparisons of various proportions and as a "physiological" approach in PCOS, with improvements in endocrine parameters, ovarian function, and insulin resistance.[6, 7]
- In practice, unit doses with a constant ratio are achieved, among other ways, in sachets (e.g., 2 g MI + 50 mg DCI, 2×/d), which facilitates maintaining the ratio with a lower "pill burden".[8]
- Excessive DCI doses pose clinical and reputational risks: paradoxical worsening of oocyte quality at high DCI doses and an increased number of immature oocytes in groups with higher DCI doses have been reported; it was also indicated that DCI can act as an aromatase inhibitor increasing androgens.[9–12]
- \"Inositol resistance\" (approx. 30–40% of patients) is mainly linked to impaired intestinal absorption; the co-ingredient α‑lactalbumin increases MI exposure (Cmax and AUC) and is described as a way to \"rescue\" the clinical response in non-responders.[13, 14]
- CoQ10 has strong points of attachment in the IVF area: 200 mg/d for 30–35 days increased CoQ10 content in follicular fluid and lowered the percentage of oxidized CoQ10, with parallel oocyte fertilization rates.[15]
- Phospholipid and emulsion technologies are useful for sensitive and/or poorly soluble ingredients: liposomes can protect (e.g., resveratrol from light/oxidation), and phytosomes can significantly increase solubility and bioavailability (e.g., silymarin complex in a phytosome).[16, 17]
- High-payload lipid systems (SEDDS/S‑SEDDS) and their \"solidification\" (e.g., spray‑drying, melt extrusion, adsorption on carriers) represent a practical path to combining multiple lipophilic antioxidants in 1–2 daily doses and to improving stability and compliance.[5, 18]
Clinical Context
PCOS is a clinical example where the coupling of metabolism with hormonal axes is systemic: cited data indicate that women with PCOS have insulin resistance, are overweight/obese, and > develop T2D and metabolic syndrome before the age of 40, which supports the thesis about the necessity of \"endocrine‑metabolic\" formulations.[2]
At the mechanistic level, MI and DCI act as insulin secondary messengers, with MI being linked to intracellular glucose transport and DCI to glycogen storage, providing a biological rationale for selecting their proportions in products aimed at insulin resistance and reproductive functions.[2]
Concurrently, reproductive processes are sensitive to redox status: oxidative stress and DNA damage result from an imbalance between ROS and antioxidant defense, and a literature review indicates potential benefits from exogenous treatment or CoQ10 supplementation in older women undergoing IVF.[3]
Inositol Stereoisomers
Myo‑inositol and D‑chiro‑inositol are inositol isomers with \"insulin‑like properties\", acting as secondary messengers in the insulin pathway, and simultaneously linked to improved insulin sensitivity of tissues and ovulatory functions.[1]
Clinical data emphasized that a combined MI + DCI supplement in a \"physiological\" ratio can improve the endocrine profile, ovarian function, and insulin resistance in PCOS patients.[6] In a study comparing multiple proportions (from to ), it was indicated that among the tested ratios, achieved the most significant results in terms of restoring ovulation and improving metabolic/hormonal parameters.[7]
In the context of IVF‑ET, data indicated that only combined therapy was able to improve oocyte and embryo quality and pregnancy-related rates in women with PCOS.[19] Simultaneously, the clinical risk of excessive DCI intake was described: with increasing doses, indications were noted that high DCI doses paradoxically worsen oocyte quality and ovarian response, and the number of immature oocytes was significantly higher in groups receiving higher DCI doses.[9, 10]
An additional safety/medical communication argument stems from the observation that DCI has been identified as an aromatase inhibitor that increases androgens and may have harmful consequences for women, reinforcing the need for \"strictly defined\" inositol supplements in PCOS instead of arbitrary mixtures.[11, 12]
Stabilization of Isomers
The industrial challenge described in the query (maintaining sensitive isomer ratios, e.g., , in a uniform high-performance matrix) in practice boils down to controlling the unit composition and limiting the risk of \"overshooting\" DCI, as sources indicate that selecting the correct MI/DCI ratio is critical to avoid dose-related DCI ovarian toxicity.[20]
In \"ready‑to‑mix\" formats, the ratio is maintained by the dosage unit design: in one of the cited schemes, each woman took a sachet 2×/d containing 2 g MI and 50 mg DCI (ratio ).[8] Concurrently, in a clinical study, MI was used in 2 g sachets dissolved in water 2×/d, demonstrating that powders in sachets are a format compatible with gram-level doses and can reduce the number of capsules while maintaining dosing rigor.[21]
Where the key problem is the repeatability of biological response and \"intestinal targeting\", an approach based on a gastro-resistant excipient and spray-drying was presented: the microparticles produced had delayed release and a preferential MI release pattern (mainly in the intestine), which was intended to \"control MI bioavailability\"; the authors explicitly stated the goal: to improve MI bioavailability and reduce the variability of the biological response after oral administration.[22] In vitro/in situ data from this solution showed approximately a 3‑fold increase in AUC for MI (AUC MPs = 4.86 vs AUC Inositol = 1.65), which is a useful parameter for justifying \"medical food technology\" in B2B communication.[22]
In the area of co‑ingredients, an important tool for \"effect stabilization\" (in the sense of clinical response, not chemical stability) is α‑lactalbumin. Sources estimated that \"inositol resistance\" affects approximately patients, and the lack of response was primarily linked to impaired intestinal absorption; α‑lactalbumin is intended to increase MI bioavailability by improving transport across the epithelium, so that effective concentrations reach the circulation and ovarian tissues.[13] In pharmacokinetic data, the combination of MI + α‑LA increased Cmax and AUC MI by respectively and vs MI administered alone, which is a measurable argument for designing products \"for non‑responders\".[14]
Liposomal and Phytosomal Delivery
In antioxidants and polyphenols, barriers to efficacy in functional foods and supplements can be limited water solubility and degradation during passage through the digestive tract, which has been directly indicated as a limiting factor for bloodstream entry; in this context, liposomes can serve as carriers for a wide range of bioactive compounds, and phytosomes as phospholipid nanocarriers improving the bioavailability of poorly water-soluble plant ingredients.[17, 23]
In the area of fertility/IVF, hard clinical-biochemical data relate to CoQ10: supplementation with 200 mg/d for 30–35 days increased CoQ10 content in follicular fluid to (+280%) and lowered the percentage of oxidized CoQ10 (27 ± 18% vs 38 ± 24% in control), and 88% of mature oocytes were fertilized in the CoQ10 group (22/25) vs 74% in control (20/27).[15] In another model (IVM), the addition of 50 mol/L CoQ10 increased oocyte maturation rates and decreased aneuploidy in women aged 38–46, which strengthens the \"mitochondrial‑redox\" narrative for peri-reproductive products (although these are ex vivo/in vitro data).[24]
For vitamin E as a lipid antioxidant, a clinical argument for synergy with CoQ10 is available: when combining CoQ10 + vitamin E, improvements in fasting glycemia, insulin, HOMA‑IR, SHBG, and total testosterone were reported in PCOS patients, and it was additionally emphasized that vitamin E can enhance the protection of oocytes against oxidative damage when co-administered with CoQ10.[25]
In polyphenols, liposomal technology is presented as a stabilization and protection tool: it was indicated that liposomes protected resveratrol from light and oxidation, increasing the amount of compound reaching the circulation; simultaneously, after 20 days of storage at , aggregation of liposomes and release of 8.92–15.26% of encapsulated compounds were observed, with coated liposomes showing lower \"leakage\".[16] In the context of industrial \"waterless lipid matrix\" solutions, the Nutrateq platform declares protection of sensitive ingredients from the aggressive gastric environment, better stability due to the anhydrous formula, and improved absorption thanks to phospholipids forming liposomes in the digestive tract.[26]
In phytosomes, specific \"proof‑of‑performance\" parameters were shown using silymarin as an example: the phytosomal complex increased water solubility (358.8 vs pure silymarin) and resulted in approximately a 6‑fold increase in systemic bioavailability; additionally, for the optimized formulation, process conditions were provided (drug:phospholipid ratio 1:1.93; ; particle size approx. 218 nm; drug content approx. 90%).[17] As a \"ready‑to‑market\" example in supplements, quercetin phytosome was also mentioned, described as \"encased in a phospholipid sphere\" with a claim of up to 20× higher bioavailability vs standard quercetin.[27]
High-Payload Matrices
SEDDS are described as an established strategy for increasing the bioavailability of poorly water-soluble compounds, as they are isotropic mixtures of oils, surfactants, and co-surfactants that spontaneously form fine oil-in-water emulsions in gastrointestinal fluids, improving solubilization and absorption; their spontaneous emulsification is supported by gastric and intestinal motility.[5, 28, 29] In terms of design parameters, typical droplet size ranges (SEDDS 100–300 nm; SMEDDS <50 nm) and mechanisms supporting bioavailability (solubilization, droplet size reduction, potential lymphatic transport) were reported.[28, 29]
For \"high‑payload\", the transition to solid form is crucial: it was indicated that the transition to solid SEDDS (S‑SEDDS) resolves liquid limitations, offering better stability, scalability, and compliance, and solidification techniques include spray‑drying, melt extrusion, and adsorption on solid carriers.[18] Simultaneously, for liposomal systems, the possibility of conversion to more stable powders through spray drying or lyophilization in the presence of stabilizers (e.g., trehalose/sucrose/biopolymers) was described to preserve vesicle integrity during dehydration and rehydration.[16]
In product practice, \"unification\" means selecting a format that can accommodate grams of MI and lipophilic antioxidants and vitamins in 1–2 doses. In available market/formulation examples, three paths are evident: (1) powders in sachets (e.g., MI 2 g 2×/d in a clinical study; or a sachet of 2 g MI + 50 mg DCI 2×/d), (2) powders/loose granules as supplements (e.g., a supplement in soluble granules in a sachet), and (3) a \"powder stick + capsules\" format (e.g., a water-soluble stick + fish oil capsule as a daily portion).[8, 21, 30, 31]
In the area of stabilizing lipophilic payloads with simultaneous \"intestinal release\", sources described the Lipomatrix platform with a molten fats core, aimed at \"entrapping lipophilic compounds into a gastric‑refractory environment\" and emulsification upon exposure to duodenal fluids; concurrently, the mechanism of gastric resistance was explained, where ascorbyl palmitate remains unionized in the stomach (pH < pKa), and in intestinal fluids (pH > pKa) undergoes partial ionization and acts as a surfactant supporting emulsification and the formation of mixed micelles with bile salts.[32]
Other Ingredients
Within the female endocrine-metabolic axis (especially PCOS), besides MI/DCI, important roles are played by ingredients targeting oxidative stress, inflammation, and insulin sensitivity, including NAC, resveratrol, melatonin, CoQ10, and \"partner nutrients\" (e.g., chromium, folic acid) in multi-ingredient formulations.[3, 4, 30, 33, 34]
NAC is described as a precursor to glutathione (a potent endogenous antioxidant) and a compound with antioxidant, anti-inflammatory, and insulin-sensitizing properties, consistent with PCOS pathophysiology.[4] Clinical effect analysis indicated that women receiving NAC had higher chances of live birth, pregnancy, and ovulation vs placebo, and meta-analytically, nearly 3× higher odds of live birth (pOR 3.00; 95% CI 1.05–8.60) were reported in one study.[35] In the metabolic area, in RCT/meta-analysis, NAC significantly lowered fasting glycemia and total cholesterol, and in the analyzed studies, the NAC dose was usually 1500 mg/d for 6–24 weeks.[36]
Resveratrol in PCOS has clinical data concerning endocrine markers and selected peri-reproductive endpoints: a meta-analysis showed a reduction in testosterone, LH, and DHEAS vs placebo, and in RCTs in PCOS, 800 mg/d for 60 days and 1000 mg/d for 3 months, among others, were administered; simultaneously, the pooled analysis showed no effect on clinical pregnancy rates vs placebo, which is important for positioning \"fertility claims\".[33, 37]
Melatonin is presented as a supplement in PCOS, and a meta-analysis of three studies (in vivo and ex vivo) showed a significant effect on clinical pregnancy rates in ART, with in vivo regimens of 3 mg from the start of the cycle or from day 3 until the trigger day; concurrently, in an RCT (n=56), a decrease in hirsutism, testosterone, hs‑CRP, and MDA, and an increase in TAC and total GSH were reported in the group receiving melatonin for 12 weeks.[34]
In multi-ingredient formulations, \"partner nutrients\" include, among others, chromium, identified as an important oligoelement for regulating insulin secretion and maintaining normal glycemia, and folic acid, described as often deficient in women of reproductive age with PCOS; supplemental examples also showed specific doses (e.g., vitamin E 36 mg, folate 400 g, chromium 40 g per serving).[30]
Medical Food
In the provided materials, \"medical food\"/food for special medical purposes is represented by products described as \"Food for special medical purposes\" or \"dietary special medical purposes\" in the context of dietary management for women with PCOS (including women desiring to conceive).[31, 38]
For example, Fertilovit® FPCOS is described as a food for special medical purposes targeting the needs of women with PCOS and containing inositol, highly dosed folic acid, and vitamin D in combination with vitamins, minerals, and omega‑3 fatty acids; it simultaneously declares the use of MI and DCI isomers in a ratio of .[31] In terms of use practice, the product assumes a \"powder stick dissolved in water + vitamin-mineral capsule + fish oil capsule\" scheme as a daily portion, which is an example of separating hydrophilic and lipophilic payloads in a single daily routine.[31]
A second example is Miositogyn, described as \"dietary special medical purposes\" for dietary management in women with menstrual disorders and PCOS, with the caveat that it is not suitable for parenteral use or as a sole source of nutrition and should be used under medical supervision; additionally, the label indicated the content of active ingredients per sachet (e.g., MI 2000 mg, NAC 600 mg, folate 400 g).[38]
Recommendations
Product design for the female endocrine-metabolic axis (PCOS, pre‑IVF/IVF) should be based on \"hard\" components that simultaneously have biological meaning (insulin‑ovary, redox‑mitochondria) and clinical evidence in the simplest possible dosing formats (sachets, powders, lipid capsules).[1–3, 15, 19, 36]
The table below summarizes combinations with relatively the strongest justification in the provided sources and suggested technological format compatible with \"high‑payload\" and reduction in the number of dosage units.
On the technological layer, if the goal is to combine multiple lipophilic antioxidants (e.g., vitamin E, resveratrol, tocotrienols) in a small number of capsules, a sensible path is SEDDS/S‑SEDDS, as they form fine emulsions in the gastrointestinal tract and can be solidified by industrial methods (spray‑drying, melt extrusion, adsorption), which enhances stability and compliance.[18, 28] For sensitive polyphenols, an additional tool is liposomes/phospholipids, which can protect against degradation (e.g., resveratrol from light/oxidation), although sources simultaneously emphasize the need for stability control (aggregation/leakage) and characterization (stability, charge, encapsulation efficiency, size).[16, 41]
Gaps and Research Directions
The provided sources confirm that the efficacy of many nutraceuticals is limited by poor oral bioavailability, which justifies investments in delivery technologies (phospholipids, SEDDS, microcarriers, spray drying to powders) and in comparative \"formulation vs formulation\" studies.[42]
In the area of liposomes and nano‑/microencapsulation systems, significant developmental risks arise: liposomes can aggregate and exhibit \"leakage\" during storage, and development documentation should include measurements of stability, surface charge, encapsulation efficiency, and size to limit quality and regulatory risks in foods/supplements.[16, 41]
At the clinical level, not all ingredients have consistent conclusions for reproductive endpoints: for example, in the case of resveratrol, a meta-analysis indicated no effect on clinical pregnancy rates vs placebo despite beneficial changes in hormonal/androgen markers, suggesting the need for better study designs and appropriate selection of endpoints in FemTech (metabolism vs fertility).[33]
In the case of ALA, caution was explicitly formulated: \"in the absence of reliable evidence\" ALA should not be routinely recommended in the clinical management of PCOS (even in combination with myo‑inositol), which implies that ALA may require a development strategy based on better data and/or more precise patient segmentation, despite the existence of mechanistic insulin premises (IRS‑1/GLUT‑4).[43, 44]
Finally, in \"high‑payload\" lipid systems, efficacy must be balanced with tolerance: technological data indicated that the effective surfactant concentration in SEDDS should be 30–60% due to the risk of gastric mucosal irritation and cytotoxicity, which affects the realistic load limits and selection of \"food‑grade\" excipients.[18]
" }